Carlyle Group’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Carlyle Group’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-192,884	Closed	-$55.9K	–	33
2024 Q2	$55.9K	Hold	192,884	–	–	0.01%	30
2024 Q1	$2.72M	Sell	192,884 -1	-0%	-$12	0.17%	19
2023 Q4	$2.23M	Hold	192,885	–	–	0.11%	20
2023 Q3	$2.87M	Hold	192,885	–	–	0.12%	21
2023 Q2	$3.95M	Hold	192,885	–	–	0.14%	20
2023 Q1	$1.69M	Buy	+192,885	New	+$2.34M	0.05%	24

Other funds holding EFTR

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Carlyle Group's EFTR Position: Q3 2024 in Review

Carlyle Group sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2024, closing a stake of 192,884 shares — an estimated $55.9K sold.

Carlyle Group first reported a position in EFTR in Q1 2023 and held it in 6 quarters. The position peaked at $3.95M in Q2 2023. 3 funds tracked by Wall St. Rank hold EFTR as of Q3 2024.

Carlyle Group reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Carlyle Group sold 192,884 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $55.9K.
Carlyle Group first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
Carlyle Group's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $3.95M in Q2 2023.
3 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Carlyle Group's 13F filing for Q3 2024, filed 8 Nov 2024.